Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at ASH23 . The updated analysis shows in CLL/SLL treatment, zanubrutinib maintains superior progression-free survival over ibrutinib.
Today at ASH I presented the updated results of the alpine study. Alpine is a phase three randomized trial that compared the next generation BT K inhibitor zanab bruin to a BRUIN. In relapse refractory CLL patients, the patients had a median of one prior therapy and were not permitted to have had prior BT K inhibitor therapy. In the previous analysis. Last year, we showed that zany brut nib was superior to a brut nib in terms of progression free survival. This is an updated analysis with 39 month follow up and the findings still hold. Zana nib showed a 10% improvement over a brut nib in progression free survival. At a landmark of three years, with 65% of patients progression free compared to 55% on the Arutt Nib arm. In the preplanned analysis of 17 P deleted patients. Our highest risk subset. This benefit was even greater at 59% progression free was ZANAB bruin. Compared to 41% with the BRUIN. The tolerability continues to be excellent for zanabin, particularly cardiac tolerability is improved over a brut nib with fewer serious cardiac adverse events, fewer discontinuations and fewer deaths due to cardiac causes. The rate of atrial fibrillation is 6.8% on the zanabin arm compared to 16% in the abut nib arm at this current follow up. So this study continues to uphold the findings of alpine that Zanabin improves progression free survival and overall response rate compared to a brut nib in relapse of factory CLL patients and suggests that Zanabin is an excellent choice for therapy of these patients.
